Back to search

Article

Dual-Targeted, Stimuli-Responsive PLGA Nanoparticles for Osteoporosis: Co-Functionalization with Bone- and Osteoclast-Specific Ligands Enables Controlled Risedronate Delivery

2025-04-30

Abstract excerpt

Osteoporosis is a widespread skeletal disease characterized by low bone mass and microarchitectural deterioration, leading to fragile bones and high fracture risk[1]. Current therapies, such as bisphosphonates and RANKL inhibitors, are effective at reducing bone loss but suffer from poor targeting, low oral bioavailability[2], and significant side effects. We propose a novel nanoparticle-based therapeutic strategy...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
995fc5fd-a339-5948-8619-dc7c26556c32
DOI
10.20944/preprints202504.2549.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Dual-Targeted, Stimuli-Responsive PLGA Nanoparticles for Osteoporosis: Co-Functionalization with Bone- and Osteoclast-Specific Ligands Enables Controlled Risedronate DeliveryDOI 10.20944/preprints202504.2549.v1
Select a neighboring publication to make it the new centre.